Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study) - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Clinical Lung Cancer Year : 2022

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)

Abstract

No abstract available
Fichier principal
Vignette du fichier
PIIS1525730422002030.pdf (498.74 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-04141332 , version 1 (26-06-2023)

Identifiers

Cite

Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, et al.. Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study). Clinical Lung Cancer, 2022, 23 (8), pp.e545-e549. ⟨10.1016/j.cllc.2022.09.002⟩. ⟨hal-04141332⟩
7 View
74 Download

Altmetric

Share

Gmail Facebook X LinkedIn More